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Introduction
The peroxisome proliferator activated
receptors (PPARs) are members of the nuclear
hormone receptor gene superfamily of ligand-
activated transcription factors [Issemann and
Green, 1990]. So far, three distinct subtypes of
PPARs have been identified, PPARa, PPARy
and PPARp/8, with each subtype encoded by
a separate gene and has a specific tissue
distribution [lssemann and Green, 1990;
Braissant et aI, 1996]. The PPARa, the first
isoform to be identified, is expressed mainly
in tissues that have high ratio of fatty acid
oxidation such as liver, heart and kidney
[Issemann and Green, 1990; Braissant et al.,
1996]. PPARa has attracted considerable
attention since it was demonstrated to be
regulators of lipoprotein metabolism [Staels et
al., 1998], vascular inflammation [Chinetti et
al., 2000], atherosclerosis [Chinetti et al.,
2000; Pineda-Torra et ai, 2002] and
carcinogenesis [Neve et al., 2000; Collett et
al., 2000]. Moreover, recent studies suggested
impoliant roles for PPARa in skin wound
healing, and epidermal maturation and repair
[Wahli,2002].
In order to understand the structure and
molecular mechanisms governing hPPARa
regulation, we carried out experiments to
identify, and characterise the 5 -untranslated
region (UTR) and promoter regions of the
hPPARa gene. In this study, we managed to
identify six differentially spliced variants in
the 5 -untranslated region (UTR) of human
PPARa gene, due to four di fferent promoter
usages and alternative splicing [Chew et al.,
2003]. Since promoter A has been
characterised [Pineda-Torra et al., 2002], three
other promoters designated as promoter B, C
and D were cloned, sequenced and their
promoter activities analysed. By carrying out
transient transfection analysis in human
hepatocarcinoma HepG2 cells, we proved
these three promoters are functional
promoters, capable of inducing the basal
luciferase gene expression, with promoter B
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being the most potent and strongest promoter
of the three promoters.
Materials and Methods
Isolation oftotal cellular RNA
Total cellular RNA was isolated from the
human hepatoma HepG2 cell line using Tri-
Reagent LS (Molecular Research Center)
according to the manufacturer's instruction.
The concentration of each total cellular RNA
was then quantified using GeneQuant
(Amersham Pharmacia Biotech).
Rapid amplification of cDNA ends (5 RLM-
RACE) and sequencing ofRACE products
5 RLM-RACE was performed on 5 Ilg
total RNA using the GeneRacer™ Kit
(Invitrogen@ Life Technologies) according to
the manufacturer's instruction. The first strand
cDNA was generated using primers supplied
by the manufacturer and subjected to two PCR
reactions. Specifically, the synthesised cDNA
was used as the template in the amplification
process using the internal gene-specific primer
GSP I (5 -GCAGG
AACTCTTCAGATAACGG-3), located at
the 5 end hPPARa exon 3 and the
GeneRacer™ 5 Primer. PCR cycling
parameters were as follows: initial
denaturation at 94°C for 3 min followed by 30
cycles of I min at 94°C, I min at 65°C, 1 min
at 60°C, and I min at noc with a final
elongation at noc for 10 min. The primary
PCR mix was then subjected to a nested PCR
under the same conditions with the
GeneRacer™ 5 Nested Primer and GSP2 (5 -
GCAGAGTGGGCTTTCCGTGT-3 )
designed immediately upstream of GSP 1.
Oligonucleotides GeneRacer™ 5 Primer and
GeneRacer™ 5 Nested Primer were provided
in the GeneRacer™ Kit. The PCR products
were size fractionated on 1.5% (w/v) agarose
gel and selected bands were then gel purified
using QIAquick gel extraction kit (QIAGEN).
The purified bands were directly ligated into
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pGEM-T Easy vector (Promega) and
transformed into JMI09. Recombinant
plasmids were then isolated and purified for
DNA sequencing using Plasmid Midi Kit
(QIAGEN). Sequencing reactions were
carried out using the ASI PRlSM@ BigDye™
Terminator Cycle Sequencing Ready Reaction
Kit (PE Applied Biosystem).
Cloning and construction of reporter-
plasmids
The promoter regions were amplified from
human genomic DNA as template with
Platinum® Pfx DNA polymerase (Invitrogen®
Life Technologies) to minimise PCR
generated mutations. These products were
then used as template for generating promoter
fragments which represent different regions of
these three promoters. The promoters'
fragments with different sizes were amplified
from the cloned promoter as template using
primers containing XhoI and HindIIl. to
facilitate the cloning into the pGL3-Basic
vector (Promega) in the correct orientation.
For promoter B, reporter-promoter plasmids,
pGL3alphBI (carrying regions -341/+34),
pGL3alphB2 (-765/+34) and pGL3alphB3 (-
1147/+34), were constructed. For promoter C,
reporter-promoter constructs were cloned and
named pGL3alphC 1 (carrying regions -
413/+41), pGL3alphC2 (-967/+41),
pGL3alphC3 (-1364/+41), while in promoter
D, reporter-promoter plasmids designated
pGL3alphDI (-395/+28), pGL3alphD2 (-
672/+28) and pGL3alphD3 (-934/+28) were
constructed.
Cell culture and transient transfection assays
Human hepatoma HepG2 cell line were
grown in Eagle's Minimum essential medi.um
with Earle's BSS medium (Gibco)
supplemented with 10% (v/v) fetal bovine
serum, 2mM L-glutamine, 100 U/ml penicillin
and 100 Ilg/m I streptomycin (Hyclone). The
cultures were maintained at 37°C in a
humidified atmosphere containing 5% (v/v)
CO2 in air. The cells were transfected with
individual promoter fragment, together with
pRL-TK containing Renilta luciferase
(Promega) which served as internal control,
using Lipofectin transfection reagent
(Invitrogen® Life Technologies) according to
the manufacturer's instructions for 36 hI's. The
luciferase activities in the cell extracts were
then determined using the Dual-Luciferase
97
Reporter Assay System (Promega). The firefly
luciferase activity was normalised to the
Renilta luciferase activity, with each
transfection being carried out in triplicate and
measurements were repeated at least twice.
Results and Discussion
Identification of Alternatively Spliced
Variants ofthe 5 UTR ofhPPARa gene
Using RLM-RACE PCR approach, six
RACE-PCR products of different sizes
(100bp, 200bp, 230bp, 300bp, 330bp and
600bp) were successfully amplified (figure
not shown). Sequencing analysis showed that
the 3 end of all RACE-PCR products shared
100% identity with the 5 end of Exon 3 of
human PPARo: gene, where the gene-specific
primers were designed, indicating that all
RACE-PCR products were specific and
represent the 5 -UTR of the human PPARo:.
Interestingly, sequence analysis amongst the
six RACE-PCR products revealed different
combination of exons which strongly indicates
the existence of 6 differentially spliced
variants in the 5 -UTR of the hPPARo: gene,
designated as hPPARo: I, hPPARo:2,
hPPARo:3, hPPARo:4, hPPARo:5 and
hPPARo:6 (Figure IA) [Chew et aI., 2003].
In addition to these six alternatively
spliced variants, we have also successfully
identified three new novel exons of the human
PPARo: gene, designated Exon A, Exon Band
Exon 2b (Figure IB) [Chew et aI., 2003].
The presence of alternatively spliced
variants in human PPARo: mRNA is a
common phenomenon amongst PPAR
isoforms. For example, four variants resulting
from four different promoters usages and
alternative splicing at the 5 -UTRs have been
identified in human PPARy mRNA [Fajas et
aI., 1997, Fajas et aI., 1998, Sundvold and
Lien, 2001], while seven alternatively spliced
variants were detected in monkey PPARy
mRNA [Zhou et aI., 2002]. In addition, four
differentially spliced variants induced by four
differential promoter usages were also
detected in mouse PPAR~ mRNA [Larsen et
aI., 2002]. Meanwhile, in porcine PPARo:
mRNA, two alternatively spliced mRNA were
found in the coding region of PPARo:
[Sundvold et aI., 2001].
Promoter D
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(A)
hPPARcd I Exon 3 I
hPPARa2 I Exon 2a I Exon 3 I
hPPARa3 I Exon A I Exon la I Exon 3
hPPARa4 I ExonB I Exon 3 I
hPPARa5 I Exon A I Exon la I Exon 2a Exon 3 I
hPPARa6 I ExonB Exon Ib I Exon 2a Exon 2b I Exon 3 I
(8)
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FIGURE 1 (A) The six alternatively spliced variants identified from this study. Alternative splicing
mechanisms and different promoters usage give rise to variants with unique combinations of exons. (B)
Schematic representation of the 5 -UTR ofhPPARo: gene. The new exons identified are indicated as shaded
boxes. Numbers in bold and in boxes represents the sizes of the introns which span the exons. Arrows
indicate the presence of promoter in front of Exon A, Exon B, Exon 2a and Exon 3.
Determination ojtranscriptional start sites
RLM-RACE method allows only full
length 5 -capped transcripts to be amplified
via the elimination of truncated mRNA,
thereby rendering it a safe, reliable and
accurate method for mapping of the 5 ends of
transcripts and transcriptional start sites of
genes [Maruyama et al., 1994, Volloch etal.,
1994]. The transcriptional start sites of Exon 3
and Exon 2a were situated 31 bp and 124 bp
upstream of the ATG initiation stalt codon in
the processed mRNA, respectively, while
exons A has two different transcriptional stalt
sites, each individually marks the stalt site
variants hPPARa3 and hPPARa5. The
transcriptional stalt site of hPPARa3 and
hPPARa5 are situated 172 bp and 264 bp
upstream of the ATG initiation stalt codon,
respectively; with the hPPARa5
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transcriptional stalt site located 8 nucleotides
upstream of the transcriptional start site of
variant PPARa3 in Exon A. Meanwhile, Exon
B also has two transcriptional stalt sites
(variant PPARa4 and variant PPAR(6)
mapped to the positions 251 bp and 540 bp
upstream of their respective ATG start codon.
The transcriptional stalt site for PPARa4 is 48
bp upstream of the transcriptional start site in
PPARa6 [Chew et al., 2003].
Multiple transcriptional start sites within
the same promoter region are in fact a
common phenomenon and frequently
observed PPAR family, i.e. in the mouse
PPARa and PPARp gene [Larsen et al., 2002,
Gearing et al., 1994].
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Cloning and analysis of the promoter regions
B, CandD
We determined the transcriptional start
sites for each variant of the human PPARo:
gene, which suggested the presence of four
promoters responsible for transcribing these
variants. Since promoter A was identified and
characterised (Pineda-Torra et al., 2002),
promoters B, C and D were chosen to be
further characterised. Direct PCR
amplifications using human genomic DNA as
template and gene-specific primers were
carried out to amplify these putative promoter
regions. Products with sizes of 1.2 kb
(promoter B), 1.5 kb (promoter C) and 1.0 kb
(promoter D) were successfully amplified.
A computer search of the putative
promoter regions using the Matisnspector
programme in TRANSFAC database
(http://transfac.gbf.de
/TRANSFAC/index.html) revealed the
existence of multiple potential binding sites
for transcription factors that may regulate the
expression of the human PPARo: gene.
Binding sites for transcription factors such as
Oct-I, AP-I, Spl, C/EBP, STAT, GATA-I,
GATA-2, HNF-3~ and RORo:I were
identified within the promoters B, C and D
regions of human PPARo: gene (figures not
shown).
Characterisation and analysis of promoters
B, C and D activities
The relative strength of the different
promoters and different fragments of the
promoters was compared by transient
transfection in Hep3B and HepG2 cells, using
various fragments of promoters' sequences.
Fragments containing regions -341/+34
(pGL3alphB I), -765/+34 (pGL3alphB2) and -
1147/+34 (pGL3alphB3) of promoter B,
fragments bearing the regions -413/+41
(pGL3alphC I), -967/+41 (pGL3alphC2) and
-1364/+41 (pGL3alphC3) of promoter C and
fragments -395/+28 (pGL3alphDI), -672/+28
(pGL3alphD2) and -934/+28 (pGL3alphD3)
of promoter D were cotransfected into the
cells with pRL-TK plasmid which served as
an internal control for transfection efficiency.
Results obtained from this study proved that
all three promoters B, C and D are functional
promoters capable of driving the basal
transcription of the luciferase gene.
99
Promoter activities for promoter B were
the highest in HepG2 cells compared to
promoter C and D, thereby indicating that
promoter B is the highest promoter of the
three, followed by promoter D being a
stronger promoter than promoter C (Figure 2).
Overall, the smallest promoter fragments
of the three promoters, pGL3alphB I (-
341/+34), pGL3alphCI (-413/+41) and
pGL3alphDI (-395/+28), proved to have the
strongest activity compared to their respective
fragments in HepG2 cells (Figure 2). This
could indicate the absence of elements
conferring transcriptional repression upstream
of the stalt sites, or alternatively, the presence
of an element enhancing transcription between
positions -341 to +34 of promoter B, positions
-413 to +41 of promoter C, and positions -395
to +28 of promoter D, or a combination of
both.
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FIGURE 2 Analysis of promoters B, C and D activities using transient transfection assays. The
promoter fragments of promoters B, C and D were fused into pGL3 basic vector and co-transfected with
pRL-TK into HepG2. Values (mean ± SD) represent firefly luciferase activity normalised to a Renilla
luciferase activity which served as internal control. Luciferase activities are shown relative to the activity of
the pGL3 basic vector. .
Conclusions
Six variants, named hPPARa1, hPPARa2,
hPPARa3, hPPARa4, hPPARa5 and
hPPARa6, were successfully identified at the
5'-UTR of human PPARa mRNA as a result
of alternatively splicing and the use of four
different promoters. Each of the
transcriptional stm1 sites of the variant was
determined and mapped, leading to the
discovery of four promoters in the human
PPARa gene which are responsible for
transcribing these alternatively spliced
variants. In addition, three new novel exons
designated Exon A, Exon Band Exon 2b were
identified in this study. Three new novel
human PPARa promoters were also cloned
and characterised. Demonstrated by transient
transfection assay, these putative promoters B,
C and D were all proven to be functional
promoters, with promoter B being the
strongest of the three promoters.
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